The 2022 WHO Classification of thyroid tumors: novel concepts in nomenclature and grading.

Abstract

The 5th edition of the Classification of Endocrine and Neuroendocrine Tumors has been released by the World Health Organization (WHO). This timely publication integrates several changes to the nomenclature of non-neoplastic and neoplastic thyroid diseases, as well as novel concepts that are essential for patient management. The heterogeneous group of non-neoplastic and benign neoplastic lesions are now collectively termed "thyroid follicular nodular disease" to better reflect the clonal and non-clonal proliferations which clinically present as multinodular goiter. Thyroid neoplasms originating from follicular-cell derived are distinctly divided into benign, low-risk and malignant neoplasms. The new classification scheme stresses that papillary thyroid carcinoma (PTC) should be subtyped based on histomorphologic features irrespective of tumor size to avoid treating all sub-centimeter/small lesions as low-risk disease. Formerly known as the cribriform-morular variant of PTC is redefined as cribriform-morular thyroid carcinoma since this tumor is now considered as a distinct malignant thyroid neoplasm of uncertain histogenesis. The "differentiated high-grade thyroid carcinoma" is a new diagnostic category including PTCs, follicular thyroid carcinomas and oncocytic carcinomas with high-grade features associated with poorer prognosis similar to the traditionally defined poorly differentiated thyroid carcinoma as per Turin criteria. In addition, squamous cell carcinoma of the thyroid is now considered a morphologic pattern/subtype of anaplastic thyroid carcinoma. In this review, we will highlight the key changes in the newly devised 5th edition of WHO classification scheme of thyroid tumors with reflections on its applicability in patient management and future directions in this field.